Table 1.
Oncolytic adenoviruses tested in current clinical trials.
| Oncolytic adenovirus | Tumor Selectivity | Route of Administration | Combination | Indication | Phases | NCT Number | Sponsor/Collaborator | Status |
|---|---|---|---|---|---|---|---|---|
| CG0070 | E2F promoter | intravesical injection | none | Bladder Cancer | Phase 2 | NCT02143804 | Cold Genesys, Inc. | Withdrawn |
| none | Phase 2 | NCT02365818 | Completed | |||||
| none | Phase 2/3 | NCT01438112 | Terminated | |||||
|
DNX2401
(Ad5-Δ24-RGD) |
24-base pair deletion in the E1A gene | Intratumoral injection |
none | Brain Cancer | Phase 1 | NCT03178032 | DNAtrix, Inc. | Recruiting |
| Intratumoral injection |
Temozolomide | Phase 1 | NCT01956734 | Completed | ||||
| Intratumoral Injection |
INF | Phase 1 | NCT02197169 | Completed | ||||
| Intratumoral Injection |
pembrolizumab | Phase 2 | NCT02798406 | Active, not recruiting | ||||
| Intra-Arterial Injection | Conventional Surgery | Brain Cancer | Phase 1 | NCT03896568 | M.D. Anderson Cancer Center, National Cancer Institute | Recruiting | ||
|
DNX2440
(Ad5-Δ24-RGD/OX40L) |
24-base pair deletion in the E1A gene | stereotactical injection |
none | Brain Cancer | Phase 1 | NCT03714334 | DNAtrix, Inc. | Recruiting |
|
LOAd703
(oAd/CD40L and 4-BBL) |
24-base pair deletion in the E1A gene | image-guided intratumoral injection | none | Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma, Colorectal Cancer | Phase 1/2 | NCT03225989 | Lokon Pharma AB | Recruiting |
| Intratumoral Injection |
gemcitabine, paclitaxel, atezolizumab | Pancreatic Cancer | Phase 1/2 | NCT02705196 | Recruiting | |||
| Intratumoral injection | atezolizumab | Malignant Melanoma | Phase 1/2 | NCT04123470 | Not yet recruiting | |||
| Enadenotucirev (ColoAd1; chimeric Ad11p/Ad3) | Unknown1 | intratumoral injection or Intravenous Infusion |
none | Colon Cancer, Non-small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma | Phase 1 | NCT02053220 | PsiOxus Therapeutics Ltd | Completed |
| Intratumoral Injection |
Capecitabine, Radiation | Locally Advanced Rectal Cancer | Phase 1 | NCT03916510 | Recruiting | |||
|
NG-641
(ColoAd1-FAP/CD3 bispecific FAP-Tac) |
intratumoral injection or Intravenous Infusion |
none | Metastatic Cancer, Epithelial Tumor | Phase 1 | NCT04053283 | Not yet recruiting | ||
|
NG-350
(ColoAd1-CD40 mAb) |
Intravesical Injection |
none | Metastatic Cancer, Epithelial Tumor | Phase 1 | NCT03852511 | Recruiting | ||
|
ONCOS-102
(oAd/GMCSF) |
24-base pair deletion in the E1A gene serotype 3 knob |
intratumoral injection or Intravenous Infusion |
none | Malignant Solid Tumour | Phase 1 | NCT01598129 | Targovax | Completed |
| Intratumoral injection | Cyclophosphamide, Pembrolizumab | Melanoma | Phase 1 | NCT03003676 | Recruiting | |||
| intratumoral injection |
Pemetrexed/cisplatin (carboplatin), Cyclophosphamide | Pleural Mesothelioma | Phase 1/2 | NCT02879669 | Active, not recruiting | |||
| intratumoral injection |
DCVac/Pca, Cyclophosphamide | Prostate Cancer | Phase 1/2 | NCT03514836 | Sotio a.s. | Recruiting | ||
|
VCN-01
(oAd/HA) |
E2F promoter regulating E1A gene | intravenous injection |
Durvalumab | Head and Neck Squamous Cell Carcinoma, | Phase 1 | NCT03799744 | VCN Biosciences, S.L. | Recruiting |
| Intravenous Injection |
Gemcitabinem, Abraxane | Pancreatic cancer | Phase 1 | NCT02045602 | Active, not recruiting | |||
| Ad5-yCD/mutTKSR39rep-ADP | replication-competent adenovirus type 5 containing a yeast cytosine deaminase(yCD)/mutant sr39 herpes simplex virus thymidine kinase fusion (yCD/mutTKsr39) gene(E1) and the 11.6 kDa adenovirus death protein (ADP) gene(E3) | Intratumoral injection |
none | Non-small Cell Lung Cancer | Phase 1 | NCT03029871 | Henry Ford Health System | Withdrawn |
| Ad5-yCD/mutTKSR39rep-hIL12 | Intraprostatic Injection |
none | Prostate Cancer | Phase 1 | NCT02555397 | Henry Ford Health System Baylor College of Medicine |
Recruiting | |
|
Ad5-yCD/mutTKSR39rep-hIL12
CGTG-102 (oAd/GMCSF) |
Intratumoral Injection |
none | Metastatic Pancreatic Cancer | Phase 1 | NCT03281382 | Recruiting | ||
| 24-base pair deletion in the E1A gene | Intratumoral Injection |
none | Tumors, Solid Tumors | Phase 1 | NCT01437280 | Withdrawn | ||
|
CadVEC
(oAd/PDL1) |
24-base pair deletion in the E1A gene | Intratumoral injection |
HER2- specific autologous CAR T | Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma | Phase 1 | NCT03740256 | Baylor College of Medicine Erasmus Medical Center, VU University Medical Center |
Not yet recruiting |
| delta-24-RGD | 24-base pair deletion in the E1A gene | Intracerebral infusion by convection enhanced delivery | none | Brain Tumor | Phase 1/2 | NCT01582516 | Completed | |
| OBP-301 | human telomerase reverse transcriptase gene (hTERT) promoter. | intratumoral injection |
none | Melanoma | Phase 2 | NCT03190824 | Syneos Health, Oncolys BioPharma Inc | Active, not recruiting |
| ORCA-010 | 24-base pair deletion in the E1A gene | intratumoral injection |
none | Prostate Cancer | Phase 1/2 | NCT04097002 | Orca Therapeutics B.V. | Not yet recruiting |
|
ICOVIR
(Ad-DM-E2F-K-Delta24-RGD) |
24-base pair deletion in the E1A gene and E2F promoter | endovenous injection |
none | Melanoma | Phase 1 | NCT01864759 | Institut Català d'Oncologia | Completed |
| ICOVIR | 24-base pair deletion in the E1A gene | intravenous injection | MSC as a delivery tool |
Solid Tumors | Phase 1/2 | NCT01844661 | Hospital Universitario Niño Jesús | Completed |
| CRAd-Survivin-pk7 | human survivin promoter | After neurosurgical resection, NSC-CRAd-S-pk7 was injected into the walls of the resection cavity | NSC as a delivery tool |
Brain Cancer | Phase 1 | NCT03072134 | Northwestern University | Recruiting |
1. Enadenociturev (previously ColoAd1) is a chimera derived from laboratory setting. Unlike other oAds that are based on naturally occurring human serotype 5 Ad, the precise biological mechanism behind the cancer specificity of enadenociturev and its derivatives have not been published. There are several probable mechanisms that may explain the cancer specificity of enadenociturev provided in Discussion section of the original paper (30).